Microsatellite instability in prostate cancer and response to immune checkpoint blockade

Authors :: Karen A. Autio
Daniel C. Danila
Susan F. Slovin
Howard I. Scher
Michael J. Morris
Nikolaus Schultz
Michael F. Berger
Sumit Middha
Charles L. Sawyers
Anuradha Gopalan
Wassim Abida
Melanie Hullings
Emily Carbone
David B. Solit
Victor E. Reuter
Joshua Armenia
Dana E. Rathkopf
Michael L. Cheng
Philip W. Kantoff
Jaclyn F. Hechtman
Source :: Journal of Clinical Oncology. 36:5020-5020
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 5020Background: Immune checkpoint blockade has shown clinical benefit in mismatch repair deficient (dMMR) cancers, leading to accelerated FDA approval of pembrolizumab, a PD1-targeting agent, for t...

Subjects :: 0301 basic medicine
Cancer Research
business.industry
Fda approval
Microsatellite instability
Pembrolizumab
medicine.disease
Immune checkpoint
Blockade
03 medical and health sciences
Prostate cancer
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
Medicine
DNA mismatch repair
business

Full Text Access

Tools